Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Two Decade Single Institution Experience Highlights Rare Survivors with Relapsed or Refractory Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 6520.

https://doi.org/10.1182/blood-2024-210617

Published: 2024

Journal Articles

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Swaminathan P Iyer, LaQuisa Hill, Steven Horwitz, Salvia Jain, Christina Poh, Julie M. Vose, Malcolm K. Brenner, Maksim Mamonkin, Sarah Hein, Federica Giordano, Alice Bexon

Blood (2024) 144 (Supplement 1): 7223.

https://doi.org/10.1182/blood-2024-201523

Published: 2024

Journal Articles

CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial

Jasmine Zain, Jeffrey Wong, Steven Horwitz, Neeta Pandit-Taskar, Anas Al-Janadi, Brandon Mancini, Rizwan Khawaja, Christina Y. Lee, Adrian Howansky, Darla Liles, Aidan Burke, Brian H. Santich, Danny Klindt Fonnes, Vignesh Rajah, Norman LaFrance, Charlotte A. Russell

Blood (2024) 144 (Supplement 1): 4434.1.

https://doi.org/10.1182/blood-2024-193628

Published: 2024

Journal Articles

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Blood (2024) 144 (Supplement 1): 4451.

https://doi.org/10.1182/blood-2024-210657

Published: 2024

Journal Articles

Characterization of Skin Response in Patients with Mycosis Fungoides and Sezary Syndrome Treated with Mogamulizumab: A Retrospective, Real World Cohort

Rachel Christensen, Robert Stuver, Stephen Dusza, Zachary D. Epstein-Peterson, Paola Ghione, Steven Horwitz, William T. Johnson, Alison Moskowitz, Patricia Myskowski, Melissa Pulitzer, Shamir Geller

Blood (2024) 144 (Supplement 1): 7790.

https://doi.org/10.1182/blood-2024-210327

Published: 2024

Journal Articles

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Blood (2024) 144 (Supplement 1): 569.

https://doi.org/10.1182/blood-2024-202537

Published: 2024

Journal Articles

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, in Patients with Non-Hodgkin's Lymphoma

Steven Horwitz, Salvia Jain, Jacob D. Soumerai, Michael T. Tees, Robert Stuver, Amro Ali, Leah Leahy, Riadh Lobbardi, Rong Chu, Eunju Hurh, Anthony S. Fiorino, Neha Mehta-Shah

Blood (2024) 144 (Supplement 1): 467.

https://doi.org/10.1182/blood-2024-210482

Published: 2024

Journal Articles

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Mark N Sorial, Sean M McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. J. Fernandez Turizo, Caroline MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra W Lenart, Emmanuel Nwodo, Jeffrey A. Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven Horwitz, Mwanasha H. Merrill, Eric D. Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie G Ford, Martina Manni, Monica Civallero, Tetiana Skrypets, Massimo Federico, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O'Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2024) 144 (Supplement 1): 465.

https://doi.org/10.1182/blood-2024-201874

Published: 2024

Journal Articles

Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 463.

https://doi.org/10.1182/blood-2024-206462

Published: 2024

Journal Articles

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Blood (2024) 144 (Supplement 1): 4434.

https://doi.org/10.1182/blood-2024-210689

Published: 2024

Journal Articles

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2024-203857

Published: 2024

Journal Articles

Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas

Blood (2024) 144 (Supplement 1): 454.

https://doi.org/10.1182/blood-2024-206518

Published: 2024

Journal Articles

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Jasmine Zain, Swaminathan P Iyer, Enrica Marchi, Mitul Gandhi, Youn H. Kim, Michael S. Khodadoust, Jonathan E. Brammer, Christina Poh, Pierluigi Porcu, Kimberley Dilley, Matthias Will, Andrea Kantor, Cathrine Leonowens, Nenad Tomasevic, H. Miles Prince, Steven Horwitz

Blood (2024) 144 (Supplement 1): 980.

https://doi.org/10.1182/blood-2024-206053

Published: 2024

Journal Articles

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Raphael Steiner, Liana Nikolaenko, Swetha Kambhampati, Niloufer Khan, Ranjit Nair, Jeremy S. Abramson, Steven Horwitz, Matthew Matasar, Colette Owens, Ildefonso Ismael Rodriguez Rivera, David J. Straus, Timothy S Pardee, Sanjeev Luther, Win Su Thet, Shreya Vemuri, Ariela Noy

Blood (2024) 144 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2024-202459

Published: 2024

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Neha Mehta-Shah, Pier Luigi Zinzani, Eric D. Jacobsen, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Ohad S Bentur, David Sidransky, Jonathan E. Brammer, Barbara Pro, Christopher P. Fox, Steven Horwitz

Blood (2024) 144 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2024-203577

Published: 2024

Journal Articles

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 3053.

https://doi.org/10.1182/blood-2024-210053

Published: 2024

Journal Articles

Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3068.

https://doi.org/10.1182/blood-2024-206398

Published: 2024

Journal Articles

A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign

Blood (2024) 144 (Supplement 1): 4474.

https://doi.org/10.1182/blood-2024-210711

Published: 2024

Journal Articles

Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 2336.

https://doi.org/10.1182/blood-2024-202741

Published: 2024

Journal Articles

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, Evelyn H. Orlando, Alison Moskowitz, Zhengming Chen, Neha Mehta-Shah, Lubomir Sokol, Steven Horwitz, Sarah C. Rutherford, Tejasvi Sahni, Ari M Melnick, Giorgio Inghirami, Leandro Cerchietti, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2024-206606

Published: 2024

NARROW

Two Decade Single Institution Experience Highlights Rare Survivors with Relapsed or Refractory Burkitt Lymphoma

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Characterization of Skin Response in Patients with Mycosis Fungoides and Sezary Syndrome Treated with Mogamulizumab: A Retrospective, Real World Cohort

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, in Patients with Non-Hodgkin's Lymphoma

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma

A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign

Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only